KLK9 (kallikrein-related peptidase 9)

Show full item record

Files in this item

PDF 09-2016-KLK9ID47324ch19q13.pdf 130.5Kb

Pour citer ce document :
URI: http://hdl.handle.net/2042/68242  |   DOI : https://doi.org/10.4267/2042/68242
Title: KLK9 (kallikrein-related peptidase 9)
Author: Adamopoulos, Panagiotis G; Scorilas, Andreas
Abstract: Kallikreins (KLKs) represent the largest cluster of serine peptidases, which is composed of 15 members (KLK1-15). The human kallikrein-related peptidase 9 gene (KLK9), like the rest of the KLK genes, encodes for a trypsin-like serine peptidase. Serine peptidases are a group of protein-cleaving enzymes that contain a serine residue in their active site. Kallikreins constitute a subfamily of serine peptidases that cleave kininogen and release vasoactive peptides (kinins). The human KLK9 gene is located at 19q13.41 and consists of 5 exons and 4 intervening introns. Although KLK9 expression has been detected in various normal human tissues, differences in mRNA and protein expression levels have been observed. Like other KLKs, KLK9 is found differentially expressed in multiple human malignancies. Clinical studies regarding the KLK9 expression analysis in breast cancer tissues have demonstrated that KLK9 mRNA expression possesses significant prognostic ability and therefore could be a strong, independent marker of favorable prognosis in patients with breast cancer. In addition, the prognostic potential of the KLK9 mRNA expression levels in ovarian cancer has been clarified, since patients with KLK9-positive tumors demonstrate significantly longer progression-free and overall survival in comparison with KLK9-negative patients. Finally, KLK9 could serve as a prognostic biomarker for patients diagnosed with high-grade astrocytoma, as its expression level is associated with decreased survival of patients. Although the precise localization and structure of the KLK9 gene has now been fully characterized, its functional roles and connections to human diseases are still incompletely understood and merit further investigation.
Subject: Kallikreins; KLK9; KLK-L3; KLKL3; biomarker; proteolytic cascades; breast cancer; ovarian cancer; astrocytoma; Genes Section; Astrocytoma/metabolism/*pathology; Biomarkers, Tumor/metabolism; Brain Neoplasms/metabolism/*pathology; Humans; Kallikreins/*metabolism; Prognosis; Survival Analysis; Tissue Array Analysis/methods; Up-Regulation; Adult; Aged; Body Fluids/*metabolism; Enzyme-Linked Immunosorbent Assay
Publisher: ARMGHM - Atlas Génétique des Cancers
Date: 2017

This item appears in the following Collection(s)

Show full item record

Advanced Search